Pair Name	Luteolin, Paclitaxel
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Down-regulation	Expression	CRIPTO	hsa6997
	Down-regulation	Expression	HMOX1	hsa3162
	Down-regulation	Expression	NFE2L2	hsa4780
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	These findings suggest that luteolin treatment significantly attenuated the hallmarks of breast cancer stemness by downregulating Nrf2-mediated expressions. Luteolin constitutes a potential agent for use in cancer stemness-targeted breast cancer treatments.

Pair Name	Luteolin, Paclitaxel
Disease Info	[ICD-11: 2B70]	Esophageal cancer		Investigative
Biological Phenomena	Inhibition-->Epithelial-mesenchymal transition
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP9	hsa842
	Up-regulation	Expression	CDH1	hsa999
	Down-regulation	Expression	CDH2	hsa1000
	Up-regulation	Expression	CLDN1	hsa9076
	Up-regulation	Phosphorylation	MAP2K4	hsa6416
	Up-regulation	Phosphorylation	MAP3K5	hsa4217
	Up-regulation	Phosphorylation	MAPK8	hsa5599
	Up-regulation	Expression	PMAIP1	hsa5366
	Up-regulation	Expression	ROS1	hsa6098
	Down-regulation	Expression	SIRT1	hsa23411
	Down-regulation	Expression	VIM	hsa7431
In Vitro Model	TE-1	Esophageal squamous cell carcinoma	Homo sapiens (Human)	CVCL_1759
	Eca-109	Esophageal squamous cell carcinoma	Homo sapiens (Human)	CVCL_6898
In Vivo Model	EC109 cells(3×10⁶) were suspended in 200μl saline and injected subcutane-ously into the right forelimb of each mouse.
Result	The molecular mechanism of inhibiting cell migration and EMT processes may be related to the inhibition of SIRT1, and the mechanism of apoptosis induction is associated with the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) pathway-mediated activation of mitochondrial apoptotic pathway.